We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BioNTech Diagnostics GmbH announced new results from a clinical performance evaluation study of the CE-marked IVD MammaTyper® which were presented at the European Society for Medical Oncology (ESMO) in Munich in October.(1,2)